Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MIMEDX GROUP, INC.MDXG · Entity 5271 | SVP & Chief Compliance Officer | May 09, 2022 | May 10, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MIMEDX GROUP, INC.
Report date May 09, 2022 · Filed May 10, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 133,608 |
Reported balance
After 2022-05-09 transaction · row 1
1 source rowRow 1 · 2022-05-09 · Sale · Disposed 3,891 · Balance 133,608 F1: The reported shares were sold in connection with the vesting of a previously granted restricted stock unit award, as required by company policy, with proceeds being used to cover the Reporting Person's tax withholding liability in connection with the vesting. F2: The purchase price indicated is a weighted average purchase price. The corresponding shares were bought in multiple transactions at prices ranging from $3.50 to $3.51, inclusive. The reporting person undertakes to provide to MiMedx Group, Inc., any security holder of MiMedx Group, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the ranges set forth herein. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported shares were sold in connection with the vesting of a previously granted restricted stock unit award, as required by company policy, with proceeds being used to cover the Reporting Person's tax withholding liability in connection with the vesting.
F2: The purchase price indicated is a weighted average purchase price. The corresponding shares were bought in multiple transactions at prices ranging from $3.50 to $3.51, inclusive. The reporting person undertakes to provide to MiMedx Group, Inc., any security holder of MiMedx Group, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the ranges set forth herein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 09, 2022 Filed May 10, 2022 20:44 UTC | MIMEDX GROUP, INC. MDXG · Entity 5271 | SaleCommon Stock | 3,891 | $3.50 | $13,621.61 |
DisclosureSEC source: 0001803893-22-000004 · wf-form4_165221547043264.xml · nonDerivative · entry 1 Graves Mark · CIK 0001803893 · SVP & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,608 F1 · shares: The reported shares were sold in connection with the vesting of a previously granted restricted stock unit award, as required by company policy, with proceeds being used to cover the Reporting Person's tax withholding liability in connection with the vesting. F2 · price: The purchase price indicated is a weighted average purchase price. The corresponding shares were bought in multiple transactions at prices ranging from $3.50 to $3.51, inclusive. The reporting person undertakes to provide to MiMedx Group, Inc., any security holder of MiMedx Group, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the ranges set forth herein. Read SEC document |
| April 08, 2022 Filed Apr 12, 2022 21:29 UTC | MIMEDX GROUP, INC. MDXG · Entity 5271 | GrantCommon Stock | 48,485 | $4.62 | $224,000.70 |
DisclosureSEC source: 0001376339-22-000043 · wf-form4_164979892542693.xml · nonDerivative · entry 1 Graves Mark · CIK 0001803893 · SVP & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,499 F1 · shares: Reflects grant of restricted stock units which will be settled in common stock following vesting. Award vests pro rata annually over three years. Grant is exempt under Rule 16b-3. Read SEC document |
| March 08, 2022 Filed Mar 10, 2022 21:27 UTC | MIMEDX GROUP, INC. MDXG · Entity 5271 | SaleCommon Stock | 3,234 | $4.86 | $15,714.01 |
DisclosureSEC source: 0001376339-22-000024 · wf-form4_164694765756055.xml · nonDerivative · entry 1 Graves Mark · CIK 0001803893 · SVP & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,014 F1 · shares: The reported shares were sold in connection with the vesting of a previously granted restricted stock unit award, as required by company policy, with proceeds being used to cover the Reporting Person's tax withholding liability in connection with the vesting. F2 · price: The sale price indicated is a weighted average sale price. The corresponding shares were sold in multiple transactions at prices ranging from $4.75 to $4.965, inclusive. The reporting person undertakes to provide to MiMedx Group, Inc., any security holder of MiMedx Group, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| February 24, 2022 Filed Feb 28, 2022 21:26 UTC | MIMEDX GROUP, INC. MDXG · Entity 5271 | SaleCommon Stock | 4,525 | $4.32 | $19,538.95 |
DisclosureSEC source: 0001803893-22-000002 · wf-form4_164608351760940.xml · nonDerivative · entry 1 Graves Mark · CIK 0001803893 · SVP & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,248 F1 · kind: The reported shares were sold in connection with the vesting of a previously granted restricted stock unit award, as required by company policy, with proceeds being used to cover the Reporting Person's tax withholding liability in connection with the vesting. F2 · price: The sale price indicated is a weighted average sale price. The corresponding shares were sold in multiple transactions at prices ranging from $4.30 to $4.35, inclusive. The reporting person undertakes to provide to MiMedx Group, Inc., any security holder of MiMedx Group, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| July 27, 2021 Filed Jul 29, 2021 12:58 UTC | MIMEDX GROUP, INC. MDXG · Entity 5271 | Tax withholdingCommon Stock | 1,505 | $12.07 | $18,165.35 |
DisclosureSEC source: 0001376339-21-000089 · wf-form4_162756349008710.xml · nonDerivative · entry 1 Graves Mark · CIK 0001803893 · SVP & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,265 F1 · kind: Represents shares withheld to pay associated taxes upon vesting of previously-granted award. Read SEC document |
| April 26, 2021 Filed Apr 27, 2021 20:34 UTC | MIMEDX GROUP, INC. MDXG · Entity 5271 | Tax withholdingCommon Stock | 3,467 | $10.63 | $36,854.21 |
DisclosureSEC source: 0001803893-21-000010 · wf-form4_161955566527739.xml · nonDerivative · entry 1 Graves Mark · CIK 0001803893 · SVP & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,770 F1 · kind: This transaction represents the netting of shares to pay applicable withholing upon vesting of previously-granted restricted stock. Read SEC document |
| March 04, 2021 Filed Mar 8, 2021 21:59 UTC | MIMEDX GROUP, INC. MDXG · Entity 5271 | GrantCommon Stock | 27,308 | $0.00 | $0.00 |
DisclosureSEC source: 0001803893-21-000008 · wf-form4_161524072791147.xml · nonDerivative · entry 1 Graves Mark · CIK 0001803893 · SVP & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,237 F1 · shares: Reflects grant of restricted stock units which will be settled in common stock following vesting. Award vests pro rata annually over three years. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 19:48 UTC | MIMEDX GROUP, INC. MDXG · Entity 5271 | Tax withholdingCommon Stock | 4,060 | $9.81 | $39,828.60 |
DisclosureSEC source: 0001803893-21-000002 · wf-form4_161402331234720.xml · nonDerivative · entry 1 Graves Mark · CIK 0001803893 · SVP & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,929 F1 · kind: This transaction represents the netting of shares to satisfy applicable witholding taxes upon the vesting of previously-granted restricted stock. Read SEC document |
| August 05, 2020 Filed Aug 6, 2020 20:44 UTC | MIMEDX GROUP, INC. MDXG · Entity 5271 | GrantCommon Stock | 35,254 | $0.00 | $0.00 |
DisclosureSEC source: 0001803893-20-000004 · wf-form4_159674666977979.xml · nonDerivative · entry 1 Graves Mark · CIK 0001803893 · SVP & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,989 F1 · price: On August 5, 2020, the Company fixed the number of shares subject to previously-awarded restricted units based on the closing stock price on that date ($5.90). Award will be settled in common stock upon vesting. One-third of the award vests upon each anniversary of the original grant date, February 18, 2020. Grant is exempt under rule 16b-3. Read SEC document |
| April 26, 2020 Filed Apr 27, 2020 20:30 UTC | MIMEDX GROUP, INC. MDXG · Entity 5271 | Tax withholdingCommon Stock | 3,363 | $3.79 | $12,745.77 |
DisclosureSEC source: 0001376339-20-000023 · wf-form4_158801943365959.xml · nonDerivative · entry 1 Graves Mark · CIK 0001803893 · SVP & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,735 F1 · kind: This transaction represents the netting of shares to satisfy applicable witholding taxes upon the vesting of previously-granted restricted stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.